Belano Medical AG: Golden Beauty Award for ibiotics skin care from BELANO medical
- Lesezeichen für Artikel anlegen
- Artikel Url in die Zwischenablage kopieren
- Artikel per Mail weiterleiten
- Artikel auf X teilen
- Artikel auf WhatsApp teilen
- Ausdrucken oder als PDF speichern
Erwähnte Instrumente
- VerkaufenKaufen
EQS-Media / 10.02.2023 / 09:00 CET/CEST
PRESS RELEASE
Golden Beauty Award for ibiotics skin care from BELANO medical
Serum regenerates natural microbiome protective shield and prevents skin aging
Hennigsdorf (Berlin), February 10, 2023 - The microbiotic serum of the skin care series "ibiotics" has been awarded the Ageless Beauty Award 2022 by the magazine "tina". The microbiome product of the first hour developed by BELANO medical received a gold medal in the category "Beauty Classics".
The core element of the "ibiotics" serum is the probiotic active ingredient "stimulans". The active ingredient and caring ingredients such as hyaluronic acids are formulated in the serum in particularly high concentrations, making it an especially effective skin care product. The serum follows a unique and patented principle developed by BELANO medical: it activates and regenerates the natural healthy skin flora so that it can optimally perform its anti-aging function. The addition of hyaluronic acids supports the anti-aging effect and gives the skin a well-groomed and fresh appearance.
Prevent aging and inflammation of the skin
Prof. Dr. Christine Lang, inventor of the active ingredient and head of research and development at BELANO medical AG, emphasized at the award ceremony that skin aging can be prevented and counteracted with the help of targeted microbiome care. "Skin aging makes the outer skin layer thinner and leads to a weakening of the antioxidant system. Ibiotics was developed to maintain and promote the natural function of our bacterial protective shield, because only a healthy and active microbiome can effectively protect the skin from free radicals and micro-inflammation."
It also reduces the risk of itching and dry, sagging skin, often the result of a dysbalance in the skin's microbiome, she said. "A decline in the skin's barrier function and chronic inflammation can be the consequences of a disturbed skin flora," says Prof. Lang.
Studies show protection of the skin through healthy microbiome
Targeted microbiome management, such as regular care with the "ibiotics" serum - as a highly concentrated biobased skin care product - can therefore make a contribution to preventing skin aging and promoting healthy skin. "The skin's healthy microbiome remains in balance or regains a healthy balance, which in turn stabilizes the skin barrier, protects the skin from harmful environmental influences and keeps inflammatory bacteria at bay."
In addition to BELANO medical's own studies, Prof. Lang also refers to research by international scientists, who most recently in 2022 once again demonstrated the importance of the skin microbiome for healthy and youthful skin in studies (for example: How Microbiomes Affect Skin Aging: The Updated Evidence and Current Perspectives, Life 2022, 12, 936. https://doi.org/10.3390/life12070936)
About BELANO medical AG:
BELANO medical AG is a biotechnology company that researches the mode of action of probiotic microorganisms and uses the results for a development of positive active ingredients in medical and care products. In doing so, novel microbiome-based therapeutic approaches for medical skin care, for the prevention of diseases and for the support of healing processes are developed and marketed. By doing so, new therapeutic options are created for diseases and indications that have not been satisfactorily treated to date. The aim is to make these patented active ingredients and their products available to everyone. The company relies on cooperation with distributors, brand manufacturers and drugstore chains in Germany and abroad.
For more information:
BELANO medical AG
Neuendorfstraße 19
16761 Hennigsdorf (Berlin), Germany
Phone: +49 (0)3302 86 37 995
End of Media Release
Issuer: Belano Medical AG
Key word(s): Enterprise
10.02.2023 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
1556447 10.02.2023 CET/CEST